Circulating Free and Low-Density Lipoprotein-Bound GD2 Can Compete with Neuroblastoma Cells for Binding Therapeutic Anti-GD2 Antibodies

Authors:

Abstract
Background: GD2 is a ganglioside that is expressed on the surface of neuroblastoma cells and shed into the circulation, where it primarily circulates bound to low density lipoprotein (LDL). We questioned whether free GD2 or GD2 bound to LDL could interfere with the binding of therapeutic anti-GD2 monoclonal antibodies like dinutuximab to neuroblastoma cells. Procedure: The GD2-expressing neuroblastoma cell line IMR5 was stained with an anti-GD2 antibody tagged with allophycocyanin (APC) at the lowest possible saturating concentration, and median fluorescence intensity was measured by flow cytometry after in vitro exposure to free GD2 or GD2 bound to LDL at concentrations of 0nM, 100nM, 1μM, and 5μM. Control experiments assessed the ability of cells with GD2 surface-expressed and GD2-non-expressing cells to compete for anti-GD2-APC antibodies with a population of 2 million IMR5 cells. Results: Free and LDL-bound GD2 reduced the binding of anti-GD2-APC antibodies to IMR5 cells in vitro in a concentration-dependent manner. At 100nM, which is below the median plasma GD2 concentration measured in patients with high-risk neuroblastoma prior to therapy, reduced antibody binding to IMR5 cells by 40%. Conclusions: At physiologic concentrations found in the plasma of patients with high-risk neuroblastoma, free GD2 and LDL-bound GD2 reduced the binding of anti-GD2 antibodies to GD2-expressing neuroblastoma cells, in vitro . This suggests that circulating GD2 could impact the efficacy of therapeutic anti-GD2 antibodies administered to patients with a high disease burden during induction therapy or at relapse.